Drug Discovery World

MAY 17, 2023

A first-in-human clinical trial of an experimental oral drug for removing radioactive contaminants from inside the body has begun. The trial is testing the safety, tolerability and processing in the body of escalating doses of the investigational drug product HOPO 14-1 in healthy adults.

Trials 130

Trials International Clinical Trials DNA 130

Drug Channels

JANUARY 16, 2024

My recent Drug Channels Outlook 2024 webinar covered 12 key trends that will shape the commercial environment this year. The video excerpt below highlights my commentary on trend #2: the rapid growth of anti-obesity GLP-1 agonist drugs. Click here to sign up for The Drug Channels 2024 Video Webinar Series.

Pharmacy 98

Pharmacy Drugs Production 98

Drug Channels

FEBRUARY 21, 2024

Below, I explain why the IRA will encourage Part D plans to prefer high-list, high-rebate specialty drugs , even as the government and manufacturers will prefer a low-list-price version. As always, I encourage you to share your own thoughts with the Drug Channels community on social media. Actually, maybe not. P.S. Want to learn more?

Biosimilars 98

Biosimilars Drugs Government Production 98

Drug Channels

DECEMBER 5, 2023

Consider two apparently unrelated drug channel anomalies: In McKesson’s 2023 fiscal year, CVS bought $75 billion in pharmaceuticals from McKesson’s wholesale business—a jump of more than 35% compared with the previous year. Despite skyrocketing sales for anti-obesity GLP-1 drugs, many retail pharmacies are losing money on every prescription.

Pharmacy 98

Pharmacy Drugs Hospitals Pharmaceuticals 98

Drug Channels

JUNE 27, 2023

Before you launch your July 4 festivities, Drug Channels offers some fireworks of our own: My $0.02 on the Humira price war—and the role of cost-plus pharmacy pricing Fresh evidence that formulary exclusions hurt patients Disturbing oncology drug benefit management Plus, an entertaining explanation of why the U.S.

Pharmacy 98

Pharmacy Drugs Biosimilars 98

Drug Channels

JUNE 1, 2023

Vishali discusses the persistent challenges of duplicate discounts between the 340B Drug Pricing Program and the Medicaid Drug Rebate Program. To learn more, sign up now for priority access to Kalderos’ 2023 annual report: Mission Critical: Bringing Drug Discount Stakeholders Together so Patients Win.

Drugs 97

Drugs 97

Drug Channels

JUNE 25, 2024

Join my nearly 57,000 LinkedIn followers for daily links to neat stuff along with commentary from the Drug Channels community. Note that we will soon migrate our social media activity to the Drug Channels Institute LinkedIn page. Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company.

Biosimilars 52

Biosimilars Drugs Pharmacy 52

Drug Channels

APRIL 29, 2024

on how Medicare Part D plans will react to the Inflation Reduction Act Walgreens' unexpected specialty pharmacy strength A video deconstruction of my infamous Drug Channels article on GoodRx Plus, a cartoonist illustrates my recent keynote on the battle for oncology margin. All rights reserved.

Specialty Pharmacies 98

Specialty Pharmacies Pharmacy Biosimilars Drugs 98

Drug Channels

MAY 29, 2024

Register now for The 340B Drug Pricing Program: Trends, Controversies, and Outlook , a new live video webinar with Adam J. Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. Summer unofficially began over the weekend. All rights reserved.

Biosimilars 52

Biosimilars Drugs Marketing 52

Drug Channels

MARCH 25, 2024

It’s finally spring in Philadelphia, home of Drug Channels. What’s ahead for the drug channel? Find out during Drug Channel Implications of the Inflation Reduction Act , a new live video webinar with Adam J. Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company.

Specialty Pharmacies 97

Specialty Pharmacies Pharmacy Hospitals Drugs 97

Drug Channels

APRIL 5, 2024

This week, I’m rerunning some popular posts while I prepare for today’s live video webinar: Drug Channel Implications of the Inflation Reduction Act. Thanks to the IRA, Part D Plans Will Prefer High-List, High-Rebate Drugs. It's time for Drug Channels ’ annual reality check on U.S. drug pricing. Details below.

Government 94

Government Drugs Production 94

Drug Channels

MAY 22, 2024

In my recent Drug Channel Implications of the Inflation Reduction Act video webinar, I explained the intended and unintended consequences of the Inflation Reduction Act of 2022 (IRA) for the commercial market and drug channel participants. © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company.

Drugs 52

Drugs Government Marketing Production 52

Drug Channels

APRIL 16, 2024

Drug Channels Institute’s (DCI’s) latest analysis finds that participants in the specialty pharmacy market continue to get more diverse—although revenues remain highly concentrated. Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. All rights reserved.

Specialty Pharmacies 96

Specialty Pharmacies Pharmacy Marketing Hospitals 96

Drug Channels

JANUARY 3, 2024

It's time for Drug Channels ’ annual reality check on U.S. drug pricing. For 2023, brand-name drugs’ list prices again grew at mid-single-digit rates. What’s more, after adjusting for overall inflation, brand-name drug net prices plunged by more than 7%. Read more » Copyright © 2006-2023 Pembroke Consulting, Inc.

Government 97

Government Drugs 97

Drug Channels

JUNE 4, 2024

It’s time for the annual update to Drug Channels Institute’s (DCI) analysis of pharmacist salaries and employment. Pharmacist employment at drug stores shrank but grew at supermarkets and mass merchants. Find out during The 340B Drug Pricing Program: Trends, Controversies, and Outlook , a new live video webinar with Adam J.

Hospitals 98

Hospitals Drugs Pharmacy 98

Drug Channels

OCTOBER 18, 2022

The biosimilar boom for provider-administered drugs continues to accelerate. Below, we share our estimates for wholesalers’ gross margins for brand-name, generic, and biosimilar drugs. We then explain the channel dynamics behind biosimilar and generic drugs’ profits. drug distribution. d/b/a Drug Channels Institute.

Biosimilars 97

Biosimilars Drugs Pharmaceuticals Production 97

Drug Channels

NOVEMBER 8, 2022

drug channel, the roles and controversies around pharmacy benefit managers (PBMs), GoodRx, Mark Cuban’s cost-plus pharmacy, the 340B Drug Pricing Program, and much more. P.S. Let me know if you’d like to see more audio/podcast content on Drug Channels. Read more » Copyright © 2006-2022 Pembroke Consulting, Inc.

Pharmacy 98

Pharmacy Drugs 98

Drug Channels

MAY 18, 2023

Read more » Copyright © 2006-2023 Pembroke Consulting, Inc. d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc. You can also visit [link]. Read on for Patrick’s insights. This Feed is for personal non-commercial use only.

Drugs 98

Drugs Pharmaceuticals 98

Drug Channels

MARCH 5, 2024

Fein, president of Drug Channels Institute (DCI) and the author of Drug Channels , invites you to join him for DCI’s latest live video webinar: Drug Channel Implications of the Inflation Reduction Act This event will be broadcast live on Friday, April 5, 2024, from 12:00 p.m. to 1:30 p.m. All rights reserved.

Pharmacy 98

Pharmacy Biosimilars Drugs Marketing 98

Drug Channels

NOVEMBER 28, 2023

In this issue: A reality check on Express Scripts’ purported “cost-based” pharmacy network Mark Cuban explains how and why the PBM market will change Why two drug prices are better than one Pharmacists sing the retail pharmacy shakeout blues Plus, two Philly legends meet at a cardiology conference! d/b/a Drug Channels Institute.

Pharmacy 97

Pharmacy Drugs Marketing 97

Drug Channels

MAY 14, 2024

Contrary to what you may have heard, the Inflation Reduction Act’s (IRA) inflation rebates for Medicare Part B drugs do not always save money for seniors. As we document below, a growing share of Part B drugs have inflation-adjusted coinsurance rates that have been increasing , not declining.

Drugs 98

Drugs 98

Drug Channels

FEBRUARY 14, 2023

This Valentine's Day, what could be more romantic than a deep dive into the relationships between manufacturers of specialty drugs and the pharmacies they choose for their limited and exclusive specialty pharmacy networks. Read more » Copyright © 2006-2023 Pembroke Consulting, Inc. d/b/a Drug Channels Institute.

Pharmacy 97

Pharmacy Specialty Pharmacies Drugs Production 97

FDA Law Blog: Drug Discovery

MARCH 7, 2024

Clissold — The trio of CDER, CBER, and CDRH released a new draft guidance titled “ Use of Data Monitoring Committees in Clinical Trials ” that revises the 2006 guidance “Establishment and Operation of Clinical Trial Data Monitoring Committees” and, when final, will replace the 2006 guidance.

Clinical Trials 105

Clinical Trials Trials FDA Regulations 105

Drug Channels

AUGUST 8, 2023

Click here to read the Drug Channels Institute letter to Senators Thune, Stabenow, Moore Capito, Baldwin, Moran, and Cardin. Read more » Copyright © 2006-2023 Pembroke Consulting, Inc. d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc. I shared my $0.02 How could I not?

Pharmacy 96

Pharmacy Hospitals Drugs Pharmaceuticals 96

Drug Channels

MAY 7, 2024

It's time for Drug Channels ’ annual update of vertical integration among insurers, PBMs, specialty pharmacies, and providers within U.S. drug channels. But until anyone takes action, we will continue to live with the golden rule of the drug channel: Whoever has the gold gets to make the rules. All rights reserved.

Specialty Pharmacies 98

Specialty Pharmacies Pharmacy Drugs 98

Drug Channels

OCTOBER 31, 2023

It's time for a super-sized Halloween roundup of wicked Drug Channels ’ tales. The gross-to-net bubble for anti-obesity GLP-1 drugs walks among us. Mark Cuban Cost Plus Drug Company conjures a partnership with Alto Pharmacy. Plus, an epic meetup with two of my favorite drug channel experts.

Biosimilars 98

Biosimilars Pharmacy Drugs 98

Drug Channels

JUNE 21, 2024

This week, I’m rerunning some popular posts while I prepare for today's live video webinar: The 340B Drug Pricing Program: Trends, Controversies, and Outlook. I found Mark’s comments to be intriguing and highly provocative, so I invited him to publish an edited version exclusively here on Drug Channels.

Drugs 98

Drugs 98

Drug Channels

NOVEMBER 14, 2023

Fein, CEO of Drug Channels Institute (DCI) and the author of Drug Channels , invites you to join him for DCI’s new live video webinar: Drug Channels Outlook 2024 This event will be broadcast live on Friday, December 15, 2023 12:00 p.m. This event is part of The Drug Channels 2023 Video Webinar Series. Dr. Adam J.

Pharmacy 98

Pharmacy Biosimilars Drugs Marketing 98

Drug Channels

APRIL 9, 2024

Read on for Drug Channels Institute’s (DCI’s) latest market share figures, along with a preview of the industry changes that will shift these shares over the next few years. Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. All rights reserved.

Pharmacy 98

Pharmacy Marketing Drugs 98

Drug Channels

MARCH 28, 2024

Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. Bill discusses specialty therapy access barriers, including payer utilization management techniques and “no coverage” policies. Contact Mercalis to learn about their Patient Support Services. Read on for Bill’s insights.

Marketing 98

Marketing Science Therapies Production 98

Drug Channels

MAY 9, 2024

Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. To learn more about navigating the complexities of market access, contact MMIT and its sister company, The Dedham Group. Read on for their insights. All rights reserved. This Feed is for personal non-commercial use only.

Therapies 98

Therapies Marketing Drugs 98

Drug Channels

MARCH 22, 2024

To learn about AssistRx’s digital intake solutions, download Digital Intake for Specialty Drug Programs: Q1 2024 Progress Report. Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. Read on for Adam’s insights. All rights reserved.

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceuticals Therapies Drugs 98

Drug Channels

SEPTEMBER 23, 2022

Lindsey describes the challenges facing remote workers who manage government-managed drug discount programs. As she explains, all drug discount stakeholders require novel technology-enabled collaboration tools. Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. d/b/a Drug Channels Institute.

Government 97

Government Drugs 97

Drug Channels

APRIL 12, 2024

Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. To learn more about enhancing patient engagement and adherence, download CareMetx's new report: Driving Brand Success: Minimize Risk and Capture Missed Value from Patient Engagement and Adherence. Read on for Jessica’s insights.

Drugs 98

Drugs 98

Drug Channels

JUNE 29, 2022

Through the Drug Channels Institute, I strive to provide you with fact-based and balanced coverage—along with links to source materials so you can make up your own mind. Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc.

Pharmacy 98

Pharmacy Drugs 98

Drug Channels

JUNE 28, 2024

Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. She goes on to describe how manufacturers can overcome these challenges to improve outcomes for both patients and brands. Click here to learn more about CoverMyMeds’ technology solutions. Read on for Kristina’s insights.

Production 52

Production Drugs 52

Drug Channels

MAY 2, 2024

Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. ET for a free online panel discussion about how brands can continue to offer robust patient support despite IRA challenges. Read on for Chris’ insights. All rights reserved. This Feed is for personal non-commercial use only.

Marketing 98

Marketing Drugs 98